secwatch.observer — SEC 8-K summary
======================================

Issuer:     Turn Therapeutics Inc. (TTRX)
CIK:        0002023016
Form:       8-K
Filed at:   2026-01-07T23:59:59+00:00
Accession:  0001213900-26-002173
Event type: leadership
Sentiment:  positive
Materiality: 0.45
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Turn Therapeutics appoints Martin Dewhurst to its Board of Directors
--------------------------------------------------------------------

- Board expanded from 5 to 6 members; Dewhurst appointed as independent Class III director effective Jan 7, 2026.
- Over 30 years life sciences experience; former McKinsey senior partner and co-leader of global life sciences practice.
- Received initial RSU grant with $100,000 fair value, vesting at one year or change of control.
- Will chair compensation committee; eligible for annual $70,000 RSU grant after first anniversary of direct listing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2023016/000121390026002173/0001213900-26-002173-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2023016/000121390026002173/ea0272109-8k_turn.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-002173

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer